These provide a potential clinical possibilities for targeting the acetylation of Lys685 of U-STAT3 and inhibition of U-STAT3 binding to p300 for cardiovascular and cerebrovascular diseases therapy. Here, STAT3 is linked to cerebrovascular disorder.